Source link : https://newshealth.biz/health-news/fda-approves-glp-1-pill-for-primary-secondary-cardiovascular-protection/
(MedPage Today) — The FDA approved oral semaglutide (Rybelsus) to prevent major adverse cardiovascular events (MACE) in high-risk patients with diabetes, whether or not they’ve had such an event already, Novo Nordisk announced. Semaglutide 7… Source link : https://www.medpagetoday.com/cardiology/generalcardiology/118042 Author : Publish date : 2025-10-20 19:21:00 Copyright for syndicated content belongs to the linked Source.
The post FDA Approves GLP-1 Pill for Primary, Secondary Cardiovascular Protection first appeared on News Health.
—-
Author : News Health
Publish date : 2025-10-20 19:21:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8